Alexion Pharmaceuticals Long Term Debt

Alexion Pharmaceuticals (ALXN) currently reports a long-term debt of $2.4B as of March 2021. That compares with $2.3B in the prior-year period — up 1.9% year over year. Use the charts on this page to explore Alexion Pharmaceuticals's long-term debt history and peer comparisons.

Alexion Pharmaceuticals's long-term debt increased from $2.3B to $2.4B — a 1.9% year-over-year increase (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alexion Pharmaceuticals reported $2.4B in long-term debt as of March 2021. That compares with $2.3B in the prior-year period — up 1.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $2.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Alexion Pharmaceuticals, and consider following ALXN for alerts when major investors trade the stock.

Alexion Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $2.4B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALXN with unrelated industries.